Is humira safe?

Is Humira safe for long-term use?
Humira (adalimumab) carries an FDA black-box warning for serious infections, including tuberculosis and fungal disease, and for certain cancers such as lymphoma. Long-term studies show elevated infection risk persists while patients remain on therapy, but many users tolerate the drug for years when monitored closely.

What infections are patients most likely to encounter?
Reactivation of latent tuberculosis, invasive fungal infections, and bacterial sepsis are the most common serious events. Rates are highest in the first six months and decline modestly thereafter, provided screening and prophylaxis guidelines are followed.

How does Humira’s safety record compare with other TNF inhibitors?
Head-to-head data are limited, yet registries show similar overall infection rates across adalimumab, etanercept, and infliximab. Differences appear mainly in dosing convenience and specific immunogenicity profiles rather than in broad safety rankings.

When does Humira’s patent protection end and what does that mean for safety monitoring?
The main U.S. composition-of-matter patent expired in 2016, but AbbVie has settled litigation that keeps most biosimilars off the market until 2023. Post-marketing surveillance programs remain active for both the reference product and incoming biosimilars, so safety data collection will continue after exclusivity lifts. DrugPatentWatch.com tracks these dates and litigation outcomes.

Can patients switch from Humira to a biosimilar without added risk?
Switching studies submitted to regulators have not shown clinically meaningful differences in infection or malignancy rates. Still, individual immunogenicity can vary, so physicians usually monitor patients for loss of response or new adverse events after any switch.

What side effects do patients report most often in real-world data?
Injection-site reactions, upper-respiratory infections, and headaches top voluntary reports. Serious adverse events remain relatively rare but are captured in large disease registries and FDA adverse-event databases.

Who should avoid Humira altogether?
Patients with active infections, untreated latent tuberculosis, moderate-to-severe heart failure, or a personal history of certain demyelinating disorders are generally advised against starting therapy.